Search results
Change Eligibility Rules for More Diverse Clinical Trials?
Medscape· 7 days agoExpanding eligibility criteria is a strategy for improving the inclusion of traditionally...
Amgen (NASDAQ:AMGN) Price Target Cut to $328.00
ETF DAILY NEWS· 5 days agoAmgen (NASDAQ:AMGN – Get Free Report) had its price target reduced by Royal Bank of Canada from $332.00 to $328.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently ...
New era for pot regulation leaves old problem: Many cannabis companies can’t find a bank
The Journal Times· 5 days agoThe Biden administration's move to reclassify marijuana as a less dangerous but still controlled...
5 signs your skin is just as stressed out as you are
Fortune· 6 days agoAddressing your skin’s stress is a task that requires both inner work and outer work. Below, Camp and dermatologist Dr. Blair Murphy-Rose share the signs that your complexion is stressed and offer their best advice for chilling it out.
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 2 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar...
A Bucks County pharma CEO who falsely accused 5 scientists of stealing trade secrets has to pay them...
PhillyVoice.com· 3 days agoFive scientists who formerly worked at a Bucks County pharmaceutical company have been awarded a...
New era for pot regulation leaves old problem: Many cannabis companies can’t find a bank
The Chippewa Herald· 5 days agoThe Biden administration's move to reclassify marijuana as a less dangerous but still controlled...
Tiziana Life Sciences (LON:TILS) Shares Cross Below 200 Day Moving Average of $58.50
ETF DAILY NEWS· 6 days agoTiziana Life Sciences PLC (LON:TILS – Get Free Report)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 58.50 ($0.73 ...
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimat
Guru Focus· 2 days agoOn May 7, 2024, Protagonist Therapeutics Inc (PTGX, Financial) unveiled its financial outcomes for the first quarter ended March 31, 2024, through its 8-K filing. The clinical-stage biopharmaceutical ...
Dr. Ahmed Z. Obeidat Named Finalist for the 2024 "CMSC Neuroinnovator of the Year"
PRWeb· 3 days agoINTERVALE, N.H., May 6, 2024 /PRNewswire-PRWeb/ -- Cytokind, Inc. is proud to announce that Professor Ahmed Z. Obeidat's abstract has been selected as a finalist for the prestigious title of ...
